Ashoke Agarwal, MD
Cardiovascular Disease · Paterson, NJNPI 1780649608
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Philips North America LLC at 34.5% of the total. Reporting peaked in 2019 at $1,028 and has fallen 92.3% since, to $79 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 55 payments — averaging $45.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$856
- Boston Scientific$398
- Medtronic$179
- AstraZeneca$146
- Abiomed$139
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- plus $641 from 11 others
What the payments were for
- Food & beverage$2,38496%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 1 | $856 |
| Boston Scientific | 3 | $398 |
| Medtronic(2 entities) | 7 | $179 |
| AstraZeneca | 5 | $146 |
| Abiomed | 1 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $125 |
| Terumo Medical Corporation | 4 | $109 |
| Shockwave Medical, Inc | 5 | $97 |
| Johnson & Johnson | 7 | $92 |
| Abbott | 4 | $90 |
| Cardiovascular Systems Inc. | 6 | $83 |
| Novartis | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Merck | 2 | $32 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$856
- WATCHMAN FLX$150
- Impella$139
- TRULANCE$125
- Watchman$125
- WATCHMAN Access System$123
How this compares
$2,484 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $125,423 |
| EntrestoSacubitril/Valsartan | 41 | $56,190 |
| JanuviaSitagliptin Phosphate | 24 | $19,189 |
| BrilintaTicagrelor | 14 | $17,260 |
| XareltoRivaroxaban | 12 | $14,882 |
| Metoprolol Succinate | 196 | $3,068 |
| ClopidogrelClopidogrel Bisulfate | 295 | $2,919 |
| Atorvastatin Calcium | 213 | $2,904 |
| Losartan Potassium | 124 | $1,458 |
| Rosuvastatin Calcium | 48 | $983 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 70 | $960 |
| Amlodipine Besylate | 171 | $915 |
| Nebivolol Hcl | 11 | $829 |
| Nitroglycerin PatchNitroglycerin | 13 | $714 |
| Nifedipine ErNifedipine | 23 | $647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $48 | $56,19041 claims |
| MerckJanuvia | $32 | $19,18924 claims |
| AstraZenecaBrilinta | $146 | $17,26014 claims |
| Johnson & JohnsonXarelto | $92 | $14,88212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Paterson
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.